{"url_path":"/sec/oprx/8-k/2026-06-12/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 ** **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1448431/0001213900-26-068272-index.html","accession_number":"0001213900-26-068272","cik":"0001448431","ticker":"OPRX","issuer_name":"OptimizeRx Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1448431/0001213900-26-068272-index.html","primary_entity_key":"0001448431","primary_entity_name":"OptimizeRx Corp"},"word_count":141,"has_tables":true,"body_markdown":"** **\n\n**Item 5.02** **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n** **\n\nOn June 9,\n2026, at the OptimizeRx Corporation (the “Company”) 2026 Annual Meeting of Shareholders (“Annual Meeting”),\nshareholders approved an amendment (the “Amendment No. 2”) to the OptimizeRx Corporation 2021 Equity Incentive Plan (the “Equity\nPlan”) to increase the number of shares of common stock (“Common Stock”) available for awards under the Equity\nPlan by 1,000,000 shares to 5,450,000 shares. A summary of the material terms of the 2021 Plan is\nincorporated herein by reference from pages 46-54 of the Company’s proxy statement for the Annual Meeting, as filed with the SEC\non April 30, 2026 (the “Proxy Statement”). The Amendment No. 2 is attached as Exhibit 10.1 to this Current Report on Form\n8-K and is incorporated by reference herein."}